Article: Rituximab for Pediatric Central Nervous System Inflammatory Disorders in Alberta, Canada.
The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques
2023 Volume 51, Issue 1, Page(s) 50–56
Abstract: Background: Early and effective treatment of central nervous system (CNS) inflammatory disorders is vital to reduce neurologic morbidity and improve long-term outcomes in affected children. Rituximab is a B-cell-depleting monoclonal antibody whose off- ... ...
Abstract | Background: Early and effective treatment of central nervous system (CNS) inflammatory disorders is vital to reduce neurologic morbidity and improve long-term outcomes in affected children. Rituximab is a B-cell-depleting monoclonal antibody whose off-label use for these disorders is funded in the province of Alberta, Canada, by the Short-Term Exceptional Drug Therapy (STEDT) program. This study describes the use of rituximab for pediatric CNS inflammatory disorders in Alberta. Methods: Rituximab applications for CNS inflammatory indications in patients <18 years of age were identified from the STEDT database between January 1, 2012, and December 31, 2019. Patient information was linked to other provincial datasets including the Discharge Abstract Database, Pharmaceutical Information Network, and Provincial Laboratory data. Analysis was descriptive. Results: Fifty-one unique rituximab applications were identified, of which 50 were approved. New applications increased from one in 2012 to a high of 12 in 2018. The most common indication was autoimmune encephalitis without a specified antibody ( Conclusion: The use of rituximab for pediatric CNS inflammatory disorders has increased, particularly for the indication of autoimmune encephalitis. This study identified significant heterogeneity in dosing practices and laboratory monitoring. Standardized protocols for the use of rituximab in these disorders and more robust outcome reporting will help better define the safety and efficacy of rituximab in this population. |
---|---|
MeSH term(s) | Humans ; Child ; Rituximab/therapeutic use ; Alberta/epidemiology ; Antibodies ; Central Nervous System Diseases/drug therapy ; Autoimmune Diseases of the Nervous System/drug therapy ; Central Nervous System ; Encephalitis ; Hashimoto Disease |
Chemical Substances | Rituximab (4F4X42SYQ6) ; Antibodies |
Language | English |
Publishing date | 2023-01-30 |
Publishing country | England |
Document type | Journal Article |
ZDB-ID | 197622-9 |
ISSN | 0317-1671 |
ISSN | 0317-1671 |
DOI | 10.1017/cjn.2023.16 |
Database | MEDical Literature Analysis and Retrieval System OnLINE |
Full text online
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
Zs.A 1203: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.